Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) Stock Competitors & Peer Comparison
See CYCN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CYCN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CYCN | $23.52 | +453.41% | 15.7M | -20.45 | -$1.15 | N/A |
| VRTX | $521.12 | -1.47% | 132.3B | 27.38 | $19.03 | N/A |
| REGN | $807.65 | -0.33% | 83.2B | 17.70 | $45.63 | +0.46% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,002.31 | -0.47% | 62.3B | 90.46 | $11.08 | N/A |
| MRNA | $135.61 | -3.36% | 53.8B | -16.64 | -$8.15 | N/A |
| RVMDW | $11.71 | +1.12% | 46B | -1.33 | -$8.82 | N/A |
| RVMD | $207.68 | +0.17% | 44.2B | -23.55 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $351.00 | -0.14% | 37.5B | 61.80 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
CYCN vs VRTX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, VRTX has a market cap of 132.3B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while VRTX trades at $521.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas VRTX's P/E ratio is 27.38. In terms of profitability, CYCN's ROE is -0.88%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, CYCN is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
CYCN vs REGN Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, REGN has a market cap of 83.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while REGN trades at $807.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas REGN's P/E ratio is 17.70. In terms of profitability, CYCN's ROE is -0.88%, compared to REGN's ROE of +0.14%. Regarding short-term risk, CYCN is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
CYCN vs VRNA Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CYCN's ROE is -0.88%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, CYCN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
CYCN vs ARGX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ARGX has a market cap of 62.3B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ARGX trades at $1,002.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ARGX's P/E ratio is 90.46. In terms of profitability, CYCN's ROE is -0.88%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, CYCN is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
CYCN vs MRNA Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, MRNA has a market cap of 53.8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while MRNA trades at $135.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas MRNA's P/E ratio is -16.64. In terms of profitability, CYCN's ROE is -0.88%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, CYCN is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
CYCN vs RVMDW Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, RVMDW has a market cap of 46B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while RVMDW trades at $11.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas RVMDW's P/E ratio is -1.33. In terms of profitability, CYCN's ROE is -0.88%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, CYCN is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
CYCN vs RVMD Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, RVMD has a market cap of 44.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while RVMD trades at $207.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas RVMD's P/E ratio is -23.55. In terms of profitability, CYCN's ROE is -0.88%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, CYCN is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
CYCN vs SGEN Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CYCN's ROE is -0.88%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CYCN is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
CYCN vs ONC Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ONC has a market cap of 37.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ONC trades at $351.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ONC's P/E ratio is 61.80. In terms of profitability, CYCN's ROE is -0.88%, compared to ONC's ROE of +0.14%. Regarding short-term risk, CYCN is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
CYCN vs ALNY Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ALNY has a market cap of 34.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ALNY trades at $258.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ALNY's P/E ratio is 46.49. In terms of profitability, CYCN's ROE is -0.88%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, CYCN is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
CYCN vs ROIV Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ROIV has a market cap of 30.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ROIV trades at $41.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ROIV's P/E ratio is -39.78. In terms of profitability, CYCN's ROE is -0.88%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, CYCN is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
CYCN vs INSM Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, INSM has a market cap of 27.9B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while INSM trades at $128.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas INSM's P/E ratio is -31.34. In terms of profitability, CYCN's ROE is -0.88%, compared to INSM's ROE of -1.11%. Regarding short-term risk, CYCN is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
CYCN vs INCY Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, INCY has a market cap of 25.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while INCY trades at $126.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas INCY's P/E ratio is 16.94. In terms of profitability, CYCN's ROE is -0.88%, compared to INCY's ROE of +0.30%. Regarding short-term risk, CYCN is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
CYCN vs BNTX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, BNTX has a market cap of 24.7B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while BNTX trades at $98.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas BNTX's P/E ratio is -12.73. In terms of profitability, CYCN's ROE is -0.88%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, CYCN is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
CYCN vs UTHR Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, UTHR has a market cap of 21.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while UTHR trades at $506.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas UTHR's P/E ratio is 18.13. In terms of profitability, CYCN's ROE is -0.88%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, CYCN is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
CYCN vs GMAB Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, GMAB has a market cap of 20.3B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while GMAB trades at $33.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas GMAB's P/E ratio is 24.90. In terms of profitability, CYCN's ROE is -0.88%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, CYCN is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
CYCN vs BGNE Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CYCN's ROE is -0.88%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, CYCN is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
CYCN vs DNA-WT Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CYCN's ROE is -0.88%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, CYCN is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
CYCN vs ASND Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ASND has a market cap of 16.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ASND trades at $260.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ASND's P/E ratio is -107.77. In terms of profitability, CYCN's ROE is -0.88%, compared to ASND's ROE of +1.90%. Regarding short-term risk, CYCN is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
CYCN vs NBIX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, NBIX has a market cap of 15.6B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while NBIX trades at $155.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas NBIX's P/E ratio is 22.42. In terms of profitability, CYCN's ROE is -0.88%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, CYCN is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
CYCN vs JAZZ Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, JAZZ has a market cap of 15.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while JAZZ trades at $241.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas JAZZ's P/E ratio is 9.00. In terms of profitability, CYCN's ROE is -0.88%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, CYCN is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
CYCN vs BBIO Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, BBIO has a market cap of 14.9B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while BBIO trades at $76.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas BBIO's P/E ratio is -20.34. In terms of profitability, CYCN's ROE is -0.88%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, CYCN is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check BBIO's competition here
Exelixis, Inc. (NASDAQ: EXEL)
CYCN vs EXEL Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while EXEL trades at $58.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas EXEL's P/E ratio is 16.67. In terms of profitability, CYCN's ROE is -0.88%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, CYCN is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
CYCN vs SMMT Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while SMMT trades at $17.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas SMMT's P/E ratio is -15.66. In terms of profitability, CYCN's ROE is -0.88%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, CYCN is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
CYCN vs HALO Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while HALO trades at $107.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas HALO's P/E ratio is 20.04. In terms of profitability, CYCN's ROE is -0.88%, compared to HALO's ROE of +1.81%. Regarding short-term risk, CYCN is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check HALO's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
CYCN vs MDGL Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, MDGL has a market cap of 12.6B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while MDGL trades at $546.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas MDGL's P/E ratio is -42.71. In terms of profitability, CYCN's ROE is -0.88%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, CYCN is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check MDGL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
CYCN vs KRTX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CYCN's ROE is -0.88%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CYCN is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
CYCN vs BMRN Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while BMRN trades at $64.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas BMRN's P/E ratio is 30.97. In terms of profitability, CYCN's ROE is -0.88%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, CYCN is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check BMRN's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
CYCN vs ARWR Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ARWR has a market cap of 11.6B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ARWR trades at $82.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ARWR's P/E ratio is -36.72. In terms of profitability, CYCN's ROE is -0.88%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, CYCN is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ARWR's competition here
Bio-Techne Corporation (NASDAQ: TECH)
CYCN vs TECH Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while TECH trades at $72.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas TECH's P/E ratio is 37.24. In terms of profitability, CYCN's ROE is -0.88%, compared to TECH's ROE of +0.09%. Regarding short-term risk, CYCN is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
CYCN vs RNAM Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CYCN's ROE is -0.88%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CYCN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
CYCN vs AXSM Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, AXSM has a market cap of 10.8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while AXSM trades at $210.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas AXSM's P/E ratio is -54.99. In terms of profitability, CYCN's ROE is -0.88%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, CYCN is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check AXSM's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
CYCN vs KRYS Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, KRYS has a market cap of 10.3B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while KRYS trades at $348.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas KRYS's P/E ratio is 43.62. In terms of profitability, CYCN's ROE is -0.88%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CYCN is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check KRYS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
CYCN vs PRAX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, PRAX has a market cap of 9.6B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while PRAX trades at $345.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas PRAX's P/E ratio is -26.71. In terms of profitability, CYCN's ROE is -0.88%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, CYCN is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check PRAX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
CYCN vs RXDX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CYCN's ROE is -0.88%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CYCN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check RXDX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
CYCN vs KYMR Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, KYMR has a market cap of 9.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while KYMR trades at $115.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas KYMR's P/E ratio is -36.07. In terms of profitability, CYCN's ROE is -0.88%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, CYCN is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check KYMR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
CYCN vs PTGX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, PTGX has a market cap of 9.3B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while PTGX trades at $145.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas PTGX's P/E ratio is 140.86. In terms of profitability, CYCN's ROE is -0.88%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, CYCN is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check PTGX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
CYCN vs IONS Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, IONS has a market cap of 9.3B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while IONS trades at $56.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas IONS's P/E ratio is -32.57. In terms of profitability, CYCN's ROE is -0.88%, compared to IONS's ROE of -1.11%. Regarding short-term risk, CYCN is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check IONS's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
CYCN vs CYTK Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while CYTK trades at $74.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas CYTK's P/E ratio is -10.26. In terms of profitability, CYCN's ROE is -0.88%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, CYCN is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check CYTK's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
CYCN vs NUVL Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas NUVL's P/E ratio is -21.79. In terms of profitability, CYCN's ROE is -0.88%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CYCN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
CYCN vs CRNX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas CRNX's P/E ratio is -16.86. In terms of profitability, CYCN's ROE is -0.88%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CYCN is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check CRNX's competition here
Abivax S.A. (NASDAQ: ABVX)
CYCN vs ABVX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ABVX has a market cap of 8.8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ABVX trades at $119.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ABVX's P/E ratio is -62.62. In terms of profitability, CYCN's ROE is -0.88%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, CYCN is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ABVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
CYCN vs IMGN Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CYCN's ROE is -0.88%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CYCN is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check IMGN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
CYCN vs PCVX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while PCVX trades at $59.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas PCVX's P/E ratio is -7.80. In terms of profitability, CYCN's ROE is -0.88%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, CYCN is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check PCVX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
CYCN vs TXG Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, TXG has a market cap of 8.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while TXG trades at $67.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas TXG's P/E ratio is -114.05. In terms of profitability, CYCN's ROE is -0.88%, compared to TXG's ROE of -0.09%. Regarding short-term risk, CYCN is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check TXG's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
CYCN vs IBRX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, IBRX has a market cap of 8.4B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while IBRX trades at $8.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas IBRX's P/E ratio is -8.31. In terms of profitability, CYCN's ROE is -0.88%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, CYCN is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
CYCN vs TGTX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, TGTX has a market cap of 8.4B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while TGTX trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas TGTX's P/E ratio is 19.80. In terms of profitability, CYCN's ROE is -0.88%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, CYCN is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
CYCN vs BPMC Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CYCN's ROE is -0.88%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, CYCN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
CYCN vs APGE Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas APGE's P/E ratio is -31.19. In terms of profitability, CYCN's ROE is -0.88%, compared to APGE's ROE of -0.30%. Regarding short-term risk, CYCN is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
CYCN vs CERE Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas CERE's P/E ratio is -16.47. In terms of profitability, CYCN's ROE is -0.88%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CYCN is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
CYCN vs IMVT Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, IMVT has a market cap of 8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while IMVT trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas IMVT's P/E ratio is -13.74. In terms of profitability, CYCN's ROE is -0.88%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, CYCN is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check IMVT's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
CYCN vs TWST Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, TWST has a market cap of 7.8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while TWST trades at $125.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas TWST's P/E ratio is -56.54. In terms of profitability, CYCN's ROE is -0.88%, compared to TWST's ROE of -0.30%. Regarding short-term risk, CYCN is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check TWST's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
CYCN vs SYRE Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, SYRE has a market cap of 7.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while SYRE trades at $86.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas SYRE's P/E ratio is -44.58. In terms of profitability, CYCN's ROE is -0.88%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, CYCN is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check SYRE's competition here
Metsera, Inc. (NASDAQ: MTSR)
CYCN vs MTSR Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CYCN's ROE is -0.88%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, CYCN is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check MTSR's competition here
Belite Bio, Inc (NASDAQ: BLTE)
CYCN vs BLTE Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, BLTE has a market cap of 7.3B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while BLTE trades at $183.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas BLTE's P/E ratio is -97.95. In terms of profitability, CYCN's ROE is -0.88%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, CYCN is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check BLTE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
CYCN vs RYTM Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, RYTM has a market cap of 6.9B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while RYTM trades at $101.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas RYTM's P/E ratio is -32.50. In terms of profitability, CYCN's ROE is -0.88%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, CYCN is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check RYTM's competition here
Merus N.V. (NASDAQ: MRUS)
CYCN vs MRUS Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CYCN's ROE is -0.88%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, CYCN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check MRUS's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
CYCN vs CAI Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, CAI has a market cap of 6.8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while CAI trades at $24.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas CAI's P/E ratio is 67.52. In terms of profitability, CYCN's ROE is -0.88%, compared to CAI's ROE of +0.19%. Regarding short-term risk, CYCN is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check CAI's competition here
Arcellx, Inc. (NASDAQ: ACLX)
CYCN vs ACLX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CYCN's ROE is -0.88%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CYCN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
CYCN vs RETA Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas RETA's P/E ratio is -66.29. In terms of profitability, CYCN's ROE is -0.88%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CYCN is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check RETA's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
CYCN vs SRRK Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, SRRK has a market cap of 6.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while SRRK trades at $54.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas SRRK's P/E ratio is -15.83. In terms of profitability, CYCN's ROE is -0.88%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, CYCN is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check SRRK's competition here
CG Oncology Inc. (NASDAQ: CGON)
CYCN vs CGON Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while CGON trades at $71.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas CGON's P/E ratio is -26.75. In terms of profitability, CYCN's ROE is -0.88%, compared to CGON's ROE of -0.25%. Regarding short-term risk, CYCN is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
CYCN vs CNTA Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas CNTA's P/E ratio is -22.63. In terms of profitability, CYCN's ROE is -0.88%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CYCN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
CYCN vs TVTX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, TVTX has a market cap of 6.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while TVTX trades at $66.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas TVTX's P/E ratio is -147.16. In terms of profitability, CYCN's ROE is -0.88%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, CYCN is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check TVTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
CYCN vs MIRM Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while MIRM trades at $98.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas MIRM's P/E ratio is -6.76. In terms of profitability, CYCN's ROE is -0.88%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, CYCN is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check MIRM's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
CYCN vs DNTH Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, DNTH has a market cap of 6B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while DNTH trades at $107.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas DNTH's P/E ratio is -25.79. In terms of profitability, CYCN's ROE is -0.88%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, CYCN is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
CYCN vs COGT Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, COGT has a market cap of 5.8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while COGT trades at $34.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas COGT's P/E ratio is -16.20. In terms of profitability, CYCN's ROE is -0.88%, compared to COGT's ROE of -0.73%. Regarding short-term risk, CYCN is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check COGT's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
CYCN vs LGND Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while LGND trades at $288.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas LGND's P/E ratio is 31.62. In terms of profitability, CYCN's ROE is -0.88%, compared to LGND's ROE of +0.20%. Regarding short-term risk, CYCN is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check LGND's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
CYCN vs XENE Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, XENE has a market cap of 5.7B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while XENE trades at $58.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas XENE's P/E ratio is -12.55. In terms of profitability, CYCN's ROE is -0.88%, compared to XENE's ROE of -0.44%. Regarding short-term risk, CYCN is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check XENE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
CYCN vs PTCT Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while PTCT trades at $67.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas PTCT's P/E ratio is -29.00. In terms of profitability, CYCN's ROE is -0.88%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, CYCN is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
CYCN vs CDTX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CYCN's ROE is -0.88%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, CYCN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
CYCN vs ABCM Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CYCN's ROE is -0.88%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CYCN is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ABCM's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
CYCN vs ORKA Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ORKA has a market cap of 5.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ORKA trades at $91.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ORKA's P/E ratio is -47.16. In terms of profitability, CYCN's ROE is -0.88%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, CYCN is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ORKA's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
CYCN vs ISEE Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CYCN's ROE is -0.88%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CYCN is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ISEE's competition here
Erasca, Inc. (NASDAQ: ERAS)
CYCN vs ERAS Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ERAS has a market cap of 5.4B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ERAS trades at $15.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ERAS's P/E ratio is -16.88. In terms of profitability, CYCN's ROE is -0.88%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, CYCN is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ERAS's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
CYCN vs APLS Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas APLS's P/E ratio is 38.35. In terms of profitability, CYCN's ROE is -0.88%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CYCN is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check APLS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
CYCN vs CRSP Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while CRSP trades at $53.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas CRSP's P/E ratio is -11.23. In terms of profitability, CYCN's ROE is -0.88%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, CYCN is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check CRSP's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
CYCN vs DFTX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while DFTX trades at $37.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas DFTX's P/E ratio is N/A. In terms of profitability, CYCN's ROE is -0.88%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, CYCN is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check DFTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
CYCN vs TERN Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas TERN's P/E ratio is -51.41. In terms of profitability, CYCN's ROE is -0.88%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CYCN is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
CYCN vs ACAD Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ACAD trades at $27.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ACAD's P/E ratio is 12.47. In terms of profitability, CYCN's ROE is -0.88%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, CYCN is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ACAD's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
CYCN vs EWTX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, EWTX has a market cap of 4.7B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while EWTX trades at $43.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas EWTX's P/E ratio is -23.45. In terms of profitability, CYCN's ROE is -0.88%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, CYCN is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check EWTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
CYCN vs FOLD Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CYCN's ROE is -0.88%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CYCN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check FOLD's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
CYCN vs PBLS Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, PBLS has a market cap of 4.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while PBLS trades at $38.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas PBLS's P/E ratio is -44.05. In terms of profitability, CYCN's ROE is -0.88%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, CYCN is more volatile compared to PBLS. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check PBLS's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
CYCN vs AKRO Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CYCN's ROE is -0.88%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, CYCN is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
CYCN vs ALPN Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CYCN's ROE is -0.88%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CYCN is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ALPN's competition here
Celcuity Inc. (NASDAQ: CELC)
CYCN vs CELC Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while CELC trades at $90.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas CELC's P/E ratio is -20.95. In terms of profitability, CYCN's ROE is -0.88%, compared to CELC's ROE of -3.51%. Regarding short-term risk, CYCN is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check CELC's competition here
Opthea Limited (NASDAQ: OPT)
CYCN vs OPT Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas OPT's P/E ratio is -1.52. In terms of profitability, CYCN's ROE is -0.88%, compared to OPT's ROE of +1.18%. Regarding short-term risk, CYCN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
CYCN vs PRTC Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas PRTC's P/E ratio is -3.78. In terms of profitability, CYCN's ROE is -0.88%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, CYCN is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check PRTC's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
CYCN vs TLX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, TLX has a market cap of 4.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while TLX trades at $12.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas TLX's P/E ratio is 128.81. In terms of profitability, CYCN's ROE is -0.88%, compared to TLX's ROE of +0.07%. Regarding short-term risk, CYCN is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check TLX's competition here
Veradermics, Incorporated (NYSE: MANE)
CYCN vs MANE Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while MANE trades at $99.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas MANE's P/E ratio is -31.76. In terms of profitability, CYCN's ROE is -0.88%, compared to MANE's ROE of -0.38%. Regarding short-term risk, CYCN is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check MANE's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
CYCN vs MRTX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CYCN's ROE is -0.88%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CYCN is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
CYCN vs ELVN Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ELVN has a market cap of 4.1B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ELVN trades at $57.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ELVN's P/E ratio is -34.40. In terms of profitability, CYCN's ROE is -0.88%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, CYCN is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ELVN's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
CYCN vs RLAY Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while RLAY trades at $18.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas RLAY's P/E ratio is -11.89. In terms of profitability, CYCN's ROE is -0.88%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, CYCN is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check RLAY's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
CYCN vs ADPT Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while ADPT trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas ADPT's P/E ratio is -59.56. In terms of profitability, CYCN's ROE is -0.88%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, CYCN is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check ADPT's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
CYCN vs TNGX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while TNGX trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas TNGX's P/E ratio is -28.92. In terms of profitability, CYCN's ROE is -0.88%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, CYCN is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check TNGX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
CYCN vs CPRX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas CPRX's P/E ratio is 12.30. In terms of profitability, CYCN's ROE is -0.88%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CYCN is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check CPRX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
CYCN vs VKTX Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while VKTX trades at $32.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas VKTX's P/E ratio is -7.02. In terms of profitability, CYCN's ROE is -0.88%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, CYCN is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check VKTX's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
CYCN vs IOVA Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, IOVA has a market cap of 3.8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while IOVA trades at $8.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas IOVA's P/E ratio is -11.55. In terms of profitability, CYCN's ROE is -0.88%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, CYCN is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check IOVA's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
CYCN vs RYZB Comparison September 2026
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYCN stands at 15.7M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CYCN is priced at $23.52 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYCN currently has a P/E ratio of -20.45, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CYCN's ROE is -0.88%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CYCN is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for CYCN.Check RYZB's competition here